

PATENT APPLICATION



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of GRILLO-LOPEZ et al.

Group Art Unit: 1644

Application No.: 09/436,348

Examiner: Ronald Schwadron

Filed: November 9, 1999

For: USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO IN VIVO PURGING  
GENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the U.S. Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


This Information Disclosure Statement is being filed more than three months after the U.S. filing date and before the mailing date of the first official action on the merits. No certification fee is required.

Respectfully Submitted,

A handwritten signature in black ink, appearing to read "TAC", with a stylized flourish at the end.

Thomas A. Cawley, Jr., Ph.D.  
Registration Number 40,944  
Customer Number: 5272

Date: October 24, 2003  
PILLSBURY WINTHROP LLP  
Telephone: (703) 905-2000  
Facsimile: (703) 905-2500  
P.O. Box 10500  
McLean, VA 22102  
TAC/JBM:ntb



Atty. Dkt. No.	M#	Client Ref.
	0275537	1998-30-0524A

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: GRILLO-LOPEZ et al.

Appln. No.: 09/436,348

Filing Date: November 9, 1999

Date: October 24, 2003 Page 1 of 1

Examiner: R. Schwadron

Group Art Unit: 1644

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR 5,530,101	06/1996	Queen et al.			
	BR 5,225,539	07/1993	Winter et al.			
	CR 4,816,397	03/1989	Boss et al.			
	DR 4,816,567	03/1989	Cabilly et al.			
	ER 5,500,362	03/1996	Robinson et al.			
	FR 5,736,137	04/1988	Anderson et al.			
	GR 6,183,744	02/2001	Goldenberg			
	HR 6,306,393	10/2001	Goldenberg			
	IR					
	JR					
	KR					
	LR					
	MR					
	NR					

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
	OR							
	PR							
	QR							
	RR							
	SR							
	TR							
	UR							
	VR							

**OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

WR	McLaughlin et al., Rituximab® chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment program, (1998), <i>J Clin Oncology</i> , 16:2825-2833.
XR	McLaughlin et al., Efficacy controls in long-term follow-up patients treated with rituximab for relapsed or refractory, low-grade or follicular NHL, (1998), <i>Blood</i> , 92:414a-415a.
YR	Janakiraman et al., Rituximab: Correlation between effector cells and clinical activity in NHL, (1998), <i>Blood</i> , 92(10 suppl 1):337a.
ZR	Rottenburger et al., Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation, (1999), <i>Br J Haematol.</i> , 106(2):545-552.

Examiner: Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.